Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Scientists from the Montreal Neurological Institute and Hospital in Canada have discovered that two genes linked to hereditary Parkinson's disease are involved in the early-stage quality control of mitochondria. The protective mechanism, which is reported in The EMBO Journal, removes damaged proteins that arise from oxidative stress from mitochondria.
"PINK1 and parkin, are implicated in selectively targeting dysfunctional components of mitochondria to the lysosome under conditions of excessive oxidative damage within the organelle," said Edward Fon, Professor at the McGill Parkinson Program at the Montreal Neurological Institute and Hospital. "Our study reveals a quality control mechanism where vesicles bud off from mitochondria and proceed to the lysosome for degradation. This method is distinct from the degradation pathway for damaged whole mitochondria which has been known for some time. It is also an early response, proceeding on a timescale of hours instead of days."
The deterioration of mechanisms designed to maintain the integrity and function of mitochondria throughout the lifetime of a cell has been suggested to underlie the progression of several neurodegenerative diseases, including Parkinson's disease. When mitochondria, the "power plants" of the cell that provide energy, malfunction they can contribute to Parkinson's disease. If they are to survive and function mitochondria need to degrade oxidized and damaged proteins.
In the study, immunofluorescence and confocal microscopy were used to observe how the vesicles "pinch off" from mitochondria with their damaged cargo. "Our conclusion is that the loss of this PINK1 and parkin-dependent trafficking system impairs the ability of mitochondria to selectively degrade oxidized and damaged proteins and leads, over time, to the mitochondrial dysfunction noted in hereditary Parkinson's disease," said Heidi McBride, Professor in the Neuromuscular Group in the Department of Neurology and Neurosurgery at the Montreal Neurological Institute and Hospital.
Both salvage pathways are operational in the cell. If the vesicular pathway, the first line of defense, is overwhelmed and the damage is irreversible then the entire organelle is targeted for degradation.
Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. Gian-Luca McLelland, Vincent Soubannier, Carol X Chen, Heidi M. McBride, Edward A. Fon. The EMBO Journal DOI: 10.1002/embj.201385902 Published 20.01.2014
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Parkinson's Disease category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
European Molecular Biology Organization. "In hereditary Parkinson's disease, quality control of mitochondria acts as a defense." Medical News Today. MediLexicon, Intl., 22 Jan. 2014. Web.
23 Apr. 2014. <http://www.medicalnewstoday.com/releases/271501>
European Molecular Biology Organization. (2014, January 22). "In hereditary Parkinson's disease, quality control of mitochondria acts as a defense." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271501.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.